StockData

C4 Therapeutics vs CRISPR Therapeutics

CCCC and CRSP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

ccccC4 Therapeutics$2.89+23.5% in 1 yearcrspCRISPR Therapeutics$45.75−16.2% in 1 year

How CCCC and CRSP compare

CRISPR Therapeutics is the larger company, worth 12 times as much as C4 Therapeutics ($4.4B against $356M).

C4 Therapeutics grew revenue faster over the last twelve months (7.2% versus −34.3% for CRISPR Therapeutics).

C4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −282% compared with −1812% at CRISPR Therapeutics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCCCCCRSP
Size and price
Market cap$356M$4.4B
Share price$2.89$45.75
Change, 1 year23.5%−16.2%
Change, 5 years−92.5%−44.5%
Beta (5Y)2.521.39
Employees104393
StockData Score
Total score88
Valuation score1 (better)0
Growth score01 (better)
Performance score22
Health score55
Dividend score00
Valuation
P/S11.0× (better)176×
P/B1.6× (better)2.7×
FCF yield−22.4%−8.5% (better)
Fair value$2.43–
Margin of safety−18.7%–
Growth
Revenue growth (TTM)7.2% (better)−34.3%
Revenue growth, 5Y average–37.3%
Profitability
Operating margin−316% (better)−2115%
Net margin−282% (better)−1812%
FCF margin−247% (better)−1497%
Return on equity−47.6%−25.6% (better)
Financial health
Debt / equity0.000.00
Current ratio5.1716.21 (better)
Altman Z-score−1.652.01 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield0.07% (better)−2.5%
Shareholder yield0.07% (better)−2.5%
Ownership
Held by institutions95.6%78.9%
Held by insiders2.8%2.7%
Insider net buying, 12 months−$22.2K (better)−$17.9M
Short interest, % of float38.9%18.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.